Impact on 2006 EPS from FAS 123(R) options expensing rules

Large cap group average -17%

Amgen -7%

Biogen Idec -10%

Celgene -14%

Genentech -9%

Genzyme -18%

Gilead Sciences -10%

MedImmune -49%

Mid cap group average -94%

Amylin Pharmaceuticals -32%

Cubist Pharmaceuticals -92%

Icos -257%

Imclone -43%

Millennium -118%

MGI Pharma -96%

Neurocrine -80%

OSI Pharmaceuticals -963%

Protein Design Labs -33%

Small cap group average -38%

Abgenix -6%

Adolor -27%

Keryx -18%

Martek -175%

Myriad Genetics -70%

NeoPharm -6%

New River -8%

Onyx Pharmaceuticals -37%

Progenics -14%

Telik -52%

Theravance -6%

Source: Merrill Lynch

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.